CN108165621A - 良性甲状腺结节特异基因 - Google Patents

良性甲状腺结节特异基因 Download PDF

Info

Publication number
CN108165621A
CN108165621A CN201611115776.3A CN201611115776A CN108165621A CN 108165621 A CN108165621 A CN 108165621A CN 201611115776 A CN201611115776 A CN 201611115776A CN 108165621 A CN108165621 A CN 108165621A
Authority
CN
China
Prior art keywords
genes
mutation
seq
ser
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201611115776.3A
Other languages
English (en)
Inventor
宁光
王卫庆
叶蕾
周晓艺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201611115776.3A priority Critical patent/CN108165621A/zh
Priority to PCT/CN2017/114889 priority patent/WO2018103679A1/zh
Priority to US16/467,573 priority patent/US20190352704A1/en
Publication of CN108165621A publication Critical patent/CN108165621A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本发明涉及良性甲状腺结节特异基因。具体地,本发明公开了三种良性甲状腺结节特异基因及其在良性甲状腺结节检测中的应用。本发明还提供了一种检测良性甲状腺结节的方法和相应的检测试剂盒。

Description

良性甲状腺结节特异基因
技术领域
本发明涉及医学检测领域,更具体地涉及三种良性甲状腺结节特异基因。
背景技术
随着常规甲状腺超声检查的普及,甲状腺结节的检出率明显上升。大规模的人群调查研究发现,女性和老年人群中甲状腺结节的患病率最高,达到19-68%。大多数新发结节都为良性结节,明确诊断为恶性的结节不到5%。虽然高分辨率超声联合细针穿刺细胞学使得甲状腺良恶性结节诊断准确率达到85%,患者与临床医生始终焦虑于良性结节是否具有恶性化潜能。因此,2009年美国甲状腺协会(ATA)推荐对于良性结节每12-18个月进行定期随访,从而造成了巨大的医疗资源与社会心理负担。
数年来,对于甲状腺结节的分子机制研究主要集中于恶性结节,甲状腺癌分子机制的研究。2014年The Cancer Genome Atlas(TCGA)甲状腺癌研究组详细描述了乳头状癌的基因组特点,发现96.5%的甲状腺乳头状癌存在明确的驱动基因变异。然而,甲状腺良性结节的遗传特征极少有研究报道。本领域迫切需要对良性甲状腺结节的遗传特征进行研究。
发明内容
本发明的目的在于提供良性甲状腺结节的特异基因。
在本发明的第一方面,提供了一种用于检测良性甲状腺结节的试剂盒,所述试剂盒包括选自下组的一对或多对引物:
(i)特异性扩增SPOP基因或转录本的引物,所述的引物扩增出长度为80-2000bp且含有SEQ ID NO.:1中第281位的扩增产物;
(ii)特异性扩增EZH1基因或转录本的引物,所述的引物扩增出长度为80-2000bp且含有SEQ ID NO.:3中第1712位的扩增产物;
(iii)特异性扩增ZNF148基因或转录本的引物,所述的引物扩增出长度为1000-3000bp且含有SEQ ID NO.:5中第1273-2871位的扩增产物。
在另一优选例中,所述特异性扩增SPOP基因或转录本的引物的核苷酸序列如SEQID NO.:7和8所示。
在另一优选例中,所述特异性扩增EZH1基因或转录本的引物的核苷酸序列如SEQID NO.:9和10所示。
在另一优选例中,所述特异性扩增ZNF148基因或转录本的引物选自下组:
(i)核苷酸序列如SEQ ID NO.:11和12所示的引物对;
(ii)核苷酸序列如SEQ ID NO.:13和14所示的引物对;
(iii)核苷酸序列如SEQ ID NO.:15和16所示的引物对。
在另一优选例中,所述试剂盒还含有选自下组的试剂:
(a)与SEQ ID NO.:1中第281位的C→G突变结合的探针或芯片;
(b)识别SEQ ID NO.:1中第281位C→G突变的限制性内切酶;
(c)与SEQ ID NO.:3中第1712位的A→G突变结合的探针或芯片;
(d)识别SEQ ID NO.:3中第1712位A→G突变的限制性内切酶。
在另一优选例中,所述的突变包括单链突变和双链突变。
在另一优选例中,所述试剂盒还含有选自下组的试剂:
(I)检测SEQ ID NO.:2中第94位P→R突变的特异性抗体;
(II)检测SEQ ID NO.:4中第571位Q→R突变的特异性抗体。
在另一优选例中,所述试剂盒用于良性甲状腺结节的辅助判断。
在另一优选例中,所述试剂盒用于甲状腺结节组织样本和/或血液样本的检测。
在另一优选例中,所述检测为预先检测。
在另一优选例中,所述的血液样品包括血清和血浆。
在另一优选例中,所述的检测是对亚洲人群进行检测。
在另一优选例中,所述的检测是对中国人群进行检测。
在本发明的第二方面,提供了一种多核苷酸分子的用途,用于制备检测良性甲状腺结节的试剂盒;其中,所述的多核苷酸分子包括:
(i)SPOP基因、特异性扩增SPOP基因或转录本的引物、与SPOP基因的核苷酸序列即SEQ ID NO.:1中第281位C→G突变特异性结合的探针或芯片、和/或检测SEQ ID NO.:2中第94位P→R突变的特异性抗体;
(ii)EZH1基因、特异性扩增EZH1基因或转录本的引物、与EZH1基因的核苷酸序列即SEQ ID NO.:3中第1712位A→G突变特异性结合的探针或芯片、和/或检测SEQ ID NO.:4中第571位Q→R突变的特异性抗体;和/或
(iii)、特异性扩增ZNF148基因或转录本的引物、与ZNF148基因的核苷酸序列即SEQ ID NO.:5中第1273-2871位突变特异性结合的探针。
在另一优选例中,所述试剂盒用于良性甲状腺结节的辅助判断。
在另一优选例中,所述试剂盒还包括一说明书,说明书中记载以下内容:
当检测对象具有一种或多种所述突变,则提示检测对象的甲状腺结节为良性。
在本发明的第三方面,提供了一种良性甲状腺结节相关基因的用途,用于制备检测良性甲状腺结节的试剂或试剂盒,并且所述的良性甲状腺结节相关基因包括SPOP基因、EZH1基因、和/或ZNF148基因。
在另一优选例中,所述的试剂或试剂盒用于检测以下单核苷酸突变:
SPOP基因的核苷酸序列:即SEQ ID NO.:1中第281位C→G。
在另一优选例中,所述的试剂包括特异性扩增SPOP基因或转录本的引物、含有所述突变位点的扩增产物、与所述突变位点特异性结合的探针、特异性检测所述突变位点的核酸芯片。
在另一优选例中,所述的试剂盒包括使用说明书以及一种或多种以下试剂:
容器(a)以及位于所述容器内的特异性扩增SPOP基因或转录本的引物;
容器(b)以及位于所述容器内的与所述突变位点特异性结合的探针;
容器(c)以及位于所述容器内的特异性检测所述突变位点的核酸芯片。
在另一优选例中,所述的SPOP基因用作标准品或对照品。
在另一优选例中,所述的试剂或试剂盒用于检测以下单核苷酸突变:
EZH1基因的核苷酸序列:即SEQ ID NO.:3中第1712位A→G。
在另一优选例中,所述的试剂包括特异性扩增EZH1基因或转录本的引物、含有所述突变位点的扩增产物、与所述突变位点特异性结合的探针、特异性检测所述突变位点的核酸芯片。
在另一优选例中,所述的试剂盒包括使用说明书以及一种或多种以下试剂:
容器(a)以及位于所述容器内的特异性扩增EZH1基因或转录本的引物;
容器(b)以及位于所述容器内的与所述突变位点特异性结合的探针;
容器(c)以及位于所述容器内的特异性检测所述突变位点的核酸芯片。
在另一优选例中,所述的EZH1基因用作标准品或对照品。
在另一优选例中,所述的试剂或试剂盒用于检测以下突变:
ZNF148基因的核苷酸序列:即SEQ ID NO.:5中第1273-2871位突变。
在另一优选例中,所述的ZNF148基因用作标准品或对照品。
在本发明的第四方面,提供了一种体外非诊断性检测样品是否存在良性甲状腺结节相关基因突变的方法,包括步骤:
(a)用特异性引物扩增样品的SPOP基因、EZH1基因、和/或ZNF148基因,得到扩增产物;和
(b)检测扩增产物中是否存在以下突变位点:
SPOP基因的核苷酸序列:即SEQ ID NO.:1中第281位C→G;
EZH1基因的核苷酸序列:即SEQ ID NO.:3中第1712位A→G;
ZNF148基因的核苷酸序列:即SEQ ID NO.:5中第1273-2871位突变。
在另一优选例中,所述的扩增产物的长度为80-2000bp且含有SEQ ID NO:1中第281位、SEQ ID NO.:3中第1712位、和/或SEQ ID NO.:5中第1273-2871位。
在另一优选例中,所述的扩增样本是甲状腺结节组织样本。
在本发明的第五方面,提供了一种检测个体良性甲状腺结节的方法,所述方法包括步骤:
检测该个体的下述基因、转录本和/或蛋白:
SPOP基因、转录本和/或蛋白,并与正常的SPOP基因、转录本和/或蛋白相比较,
EZH1基因、转录本和/或蛋白,并与正常的EZH1基因、转录本和/或蛋白相比较,
ZNF148基因、转录本和/或蛋白,并与正常的ZNF148基因、转录本和/或蛋白相比较,
其中,存在差异就提示该个体的甲状腺结节为良性。
在另一优选例中,检测待测个体结节样本中的基因、转录本和/或蛋白,并与该个体血液样本中的基因、转录本和/或蛋白相比较。
在另一优选例中,所述的差异是存在以下突变:
SPOP基因的核苷酸序列即SEQ ID NO.:1中第281位C→G;
EZH1基因的核苷酸序列即SEQ ID NO.:3中第1712位A→G;
ZNF148基因的核苷酸序列即SEQ ID NO.:5中第1273-2871位发生突变。
在另一优选例中,对个体的甲状腺结节组织样本进行检测,从而检测个体甲状腺结节是否为良性。
应理解,在本发明范围内中,本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。限于篇幅,在此不再一一累述。
具体实施方式
本发明人经过广泛而深入地研究,首次意外地发现与三种性结节相关的基因,分别是SPOP基因、EZH1基因和ZNF148基因。实验表明,SPOP,EZH1和ZNF148为互不相交的基因突变,在29.2%的良性结节中出现,在配对的PTC肿瘤组织中不发生。上述3个良性结节相关基因,提供了恶性甲状腺结节的“排除”信息,在基因突变检测中有重要诊断意义。
SPOP基因
SPOP基因(NM_001007226)编码的蛋白调节死亡相关蛋白(DAXX)的转录抑制活性,DAXX与组蛋白去乙酰化酶、核心组蛋白和其他组蛋白相关蛋白相互作用。在小鼠中,SPOP编码的蛋白结合到macroH2A1.2的亮氨酸拉链结构域,后者是H2A组蛋白的异构体,富集在失活的X染色体上。此蛋白的BTB/POZ结构域与其他蛋白作用,调节转录抑制活性,与组蛋白去乙酰化酶的共抑制复合物的组件相互作用。SPOP基因的选择性剪切会产生许多转录变异体,编码相同的蛋白。
EZH1基因
EZH1基因(NM_001991)编码的蛋白是一个非经典的多梳抑制复合物2(PRC-2)的组成部分,调节组蛋白H3第27位赖氨酸(H3K27)的甲基化作用,在维持胚胎干细胞的多能性和可塑性中起重要作用。
ZNF148基因
ZNF148基因(NM_021964)编码的蛋白(锌指蛋白148)属于Krüppel-like转录因子的一类,对其目标蛋白既有转录激活作用也可抑制转录。ZNF148的低表达与结直肠癌的预后不良相关,在肝细胞癌细胞系中,ZNF148过表达的克隆形成明显减少。
甲状腺结节
甲状腺结节是指在甲状腺内的肿块,可随吞咽动作随甲状腺而上下移动,是临床常见的病症,可由多种病因引起。临床上有多种甲状腺疾病,如甲状腺退行性变、炎症、自身免疫以及新生物等都可以表现为结节。甲状腺结节可以单发,也可以多发,多发结节比单发结节的发病率高,但单发结节甲状腺癌的发生率较高。
甲状腺结节分为良性甲状腺结节和恶性甲状腺结节,大多数新发结节都为良性结节,明确诊断为恶性的结节不到5%。
检测方法、检测试剂及试剂盒
本发明提供了一种检测个体良性甲状腺结节的方法,通过检测甲状腺结节中的SPOP基因、EZH1基因、和ZNF148基因,并将其与血液样本中的相应基因进行比较,提前预测甲状腺结节是否为良性。本发明的方法可以用于辅助诊断分型,尤其是早期辅助性诊断。
具体地,本发明的方法、试剂及试剂盒检测如下突变:
本领域的技术人员知道,有大量的分析技术可用于检测基因中所述位点是否存在突变。这些技术包括(但并不限于):DNA测序、杂交测序;酶促错配切割、异源双链分析、点杂交、寡核苷酸阵列(芯片)、焦磷酸测序、Taqman探针检测技术、分子信标等。
用于本发明的测试样品没有特别限制,对于检测突变位点而言,可以是从细胞或组织等样品中抽提出的DNA或mRNA。由于本发明的突变主要存在于甲状腺结节细胞中,通常而不存在于外周血细胞中。因此,优选的测试样品是甲状腺结节细胞,外周血细胞可以用作对照。
本发明的基因序列检测的一部分或全部可作为探针固定在微阵列(microarray)或DNA芯片(又称为“基因芯片”或“核酸芯片”)上,用于分析组织中基因的序列和差异表达分析,以及基因诊断。用SPOP基因、EZH1基因、和ZNF148基因的特异性引物进行RNA-聚合酶链反应(RT-PCR)体外扩增也可检测相应的转录产物。
检测可以针对cDNA,也可针对基因组DNA。SPOP基因、EZH1基因、和ZNF148基因的突变的形式包括与正常野生型DNA序列相比的点突变、易位、缺失、重组和其它任何异常等。可用已有的技术如Southern印迹法、DNA序列分析、PCR和原位杂交检测突变。另外,突变有可能影响相关蛋白的表达,因此用Northern印迹法、Western印迹法可间接判断基因有无突变。
最方便的检测本发明突变位点的方法,是通过用SPOP基因、EZH1基因、和ZNF148基因的特异性引物分别扩增样品的SPOP基因、EZH1基因、和ZNF148基因,得到扩增产物;然后检测扩增产物中是否存本发明的单核苷酸突变(SNV)。
具体地,可用于检测的代表性引物序列如下所示:
SPOP引物序列:
F:CCAGATCAAAGCCACAAC(SEQ ID NO.:7)
R:CTGGACGATAGAGTAAGACC(SEQ ID NO.:8)
EZH1引物序列:
F:ACACCTGCTTTTTTGACTCG(SEQ ID NO.:9)
R:AACCAGTGGAAAGAGAATGC(SEQ ID NO.:10)
ZNF148最后一个外显子引物序列:
1)F:TCTTGGTTGACCAAAACCAC(SEQ ID NO.:11)
R:GGCCCCTCCTGCAAATTATC(SEQ ID NO.:12)
2)F:TTTGGGAGGGTCTGGTTATC(SEQ ID NO.:13)
R:CCACATATGAAGAGAGCAAAG(SEQ ID NO.:14)
3)F:CAGGCTTTGGACAGAACTAG(SEQ ID NO.:15)
R:TACACAGAGTAACCCCACTC(SEQ ID NO.:16)
应理解,在本发明首次揭示了SPOP基因、EZH1基因、和ZNF148基因的突变位点与良性甲状腺结节的相关性之后,本领域技术人员可以方便地设计出可特异性扩增出含该突变位点位置的扩增产物,然后通过测序等方法确定是否存在本发明的突变。通常,引物的长度为15-50bp,较佳地为20-30bp。虽然引物与模板序列完全互补是优选的,但是本领域技术人员知道,在引物与模板存在一定的不互补(尤其是引物的5'端)的情况下,也能够特异性地扩增(即仅扩增出所需的片段)。含有这些引物的试剂盒和使用这些引物的方法都在本发明范围之内,只要该引物扩增出的扩增产物含有本发明基因突变位点的对应位置。
虽然扩增产物的长度没有特别限制,但是通常扩增产物的长度为100-2000bp,较佳地为150-1500bp,更佳地为200-1000bp。这些扩增产物都应含有本发明的单核苷酸突变(SNV)位点。
本发明的主要优点包括:
(a)发现SPOP,EZH1和ZNF148这3个良性结节相关基因,提供了甲状腺乳头状癌的“排除”信息;
(b)强有力地证实了大部分良性结节并非癌前状态,与乳头状癌的发生无关;
(c)存在SPOP,ZNF148,或EZH1突变时,可能无需对良性甲状腺结节进行常规监测,节省大量医疗资源。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数按重量计算。
通用材料和方法
样本准备和DNA提取
经上海交通大学医学院附属瑞金医院伦理委员会批准,并在患者知情同意后,从28位患者的手术标本中共获得127例组织样本,其中包括21位伴癌结节患者(同时患有甲状腺良性结节和甲状腺乳头状癌)与8位单纯良性结节患者。单纯良性结节定义为至少患有一个甲状腺结节并存在时间大于2年,且无恶性组织学征象。所有患者在标本采集前均未接受治疗(放疗或化疗)。使用患者血液标本作为生殖细胞系对照(以识别体细胞变异)。所有组织收集时迅速放入液氮中储存,并独立分析,以最大程度减少污染和干扰。经有经验的病理科医师检阅核对HE染色切片后,对病理证实的区域提取DNA(甲状腺乳头状癌组织的细胞密度>80%)。使用数字病理切片扫描仪nanozoomer 2.0-RS(Hamamatsu)扫描病理切片,并使用QIAGEN DNeasy Blood&Tissue Kit提取组织DNA。对于伴癌结节患者,同时收集良性结节、乳头状癌和正常组织;对于单纯结节患者,收集良性结节和配对的正常甲状腺组织。
全外显子组测序
通过超声组织匀浆仪将28例患者共127个组织DNA随机打碎成小片段,构建测序文库,平均插入片段大小为300bp。使用SureSelect Human All Exon 50Mb kit(AgilentTechnologies,Santa Clara,CA)进行全外显子组捕捉,再用Illumina HiSeq2500测序系统进行深度测序,生成100bp的配对序列。所有样本测序数据经过严格过滤后,得到平均为13.26GB数据量的高质量原始测序数据(全外显子测序的平均有效覆盖为161x,最低为130倍覆盖,最高为180倍)。
变异位点的注释和命名
使用BWA软件(第0.7版),采用其默认参数设置,将获得的全外显子测序的配对序列与人类参考基因组(hg19)进行序列比对。PCR扩增造成的重复产物使用Picard工具(1.1版)进行去除。在有插入或缺失突变的局部区域,重新进行序列比对,并矫正碱基质量打分。经过这些分析,最后获得BAM文件(二进制比对文件),使用GATK软件包中的UnifiedGenotyper模块识别突变位点。为了比较具体每个患者配对组织的突变情况,在GATK联合识别体细胞突变位点的基础上,使用单个正常组织-多个肿瘤样本的策略。为避免测序或比对过程中的误差,采用以下标准:1)组织和对照血样都要有完整、足够的序列覆盖(至少10x深度);2)组织中覆盖某个位点的序列中,至少10%支持此处有突变碱基(如果局部深度>50倍,则设为5%);3)组织中,测序数据中发现突变至少要超过3次。4)对每个可能的体细胞突变位点,使用卡方检验检测多个组织和对照血样的等位基因深度和频率;5)排除对照血样品中也出现突变的位点(大于2个序列支持血样中也发生突变)。后续分析中,排除dbSNP数据库中的常见突变(build 142)、千人基因组中(最小等位基因频率MAF>5%)、exome aggregation consortium数据库中(MAF>1%)、内含子区域和基因间隔区的突变。使用ANNOVAR软件对体细胞突变的单碱基突变(SNV)和插入缺失突变进行注释,找出位于的基因及可能受影响的蛋白编码。
突变分析
假设人类外显子的蛋白编码基因共30Mb并完全覆盖,计算突变密度。体细胞突变的碱基使用前述的SNV分析结果。分析良性肿瘤的共有突变时,比较配对肿瘤和良性结节的突变序列,以找到良性肿瘤特有的重要突变。
使用PCR和Sanger一代测序验证突变
对全外显子组测序发现的变异位点,进一步使用96孔板进行PCR检测验证(GeneAmp PCR系统9700,由法国的Biosystems提供),每个反应使用20ng的DNA模板。PCR产物由3730xl DNA Analyzer(Applied Biosystems,Courtaboeuf,France)测序,并使用测序分析软件(5.2版本Applied Biosystems,Courtaboeuf,France)进行分析。所有阳性的突变均根据原始测序的trace文件通过了人工核对得到了确认。
扩大群体评估良性结节中重要突变的频率
进一步收集了259例患者共328例液氮冰冻的甲状腺良性结节组织。按上述方法抽提基因组DNA,对SPOPP94R和EZH1Q571R热点突变位点,设计引物对位点所在外显子区段进行PCR扩增,并使用Sanger测序方法对PCR产物进行测序,根据原始测序的trace文件人工核对确认变异,计算变异频率。对于ZNF148基因(NM_021964),由于全外显子组发现多个位于最后一个外显子的变异,因此设计PCR产物,对所有编码区域和内含子-外显子连接区域的侧翼逐一测序,统计整个ZNF148编码区的变异。
研究结果
在28位患者的样本库中,共发现了535个基因的734个体细胞突变。良性结节中的突变频率(每Mb有0.36个突变)实际上高于乳头状癌(每Mb有0.33个突变)(P=0.58)。经比较,来源于PTC组和非PTC组的良性结节的突变频率无明显差异(分别为每Mb有0.34和每Mb有0.38个突变,P=0.70,t检验)。
28位患者的良性结节中,最常见的频发突变为SPOP(有4位患者中检出,14.3%),EZH1(有3位患者中检出,10.7%)和ZNF148(有6位患者中检出,21.4%)。SPOP和EZH1均为热点突变,分别为(P94R)和(Q571R);ZNF148的突变均位于最后一个外显子,为无义突变或移码突变。甲状腺癌的TCGA数据库中,这三个基因的发生率极低(几千份样本中,只发现有1个SPOP,2个EZH1,2个ZNF148),且均同时伴有已知的PTC驱动突变。
为扩大样本验证这三个基因与甲状腺良性结节的特异关系,对231例额外的良性甲状腺结节患者进行检测,结果发现,231例患者中,有29例患者(11.2%)存在SPOPP94R突变,24例患者存在EZH1Q571R突变,14例患者存在ZNF148突变(5.4%),每个突变互不相交。
讨论
甲状腺结节形成是甲状腺肿大的原发早期刺激因素。结节形成的原因包括碘缺乏、营养性甲状腺肿或自身免疫疾病。相比之下,滤泡上皮细胞的局部增殖导致的甲状腺结节形成为单克隆增殖,且由体细胞突变引起。甲功正常的甲状腺结节中,仅有一小部分发生TSHR,GNAS,或RAS家族基因的体细胞突变。此外,多结节疾病中尚不清楚是否有特异的亚群为癌前病变。利用全外显子测序技术首次描述了良性甲状腺结节的基因突变情况。有趣的是,发明人发现虽然良性结节和乳头状癌的基因突变频率相似,但特异的基因却各不相同。SPOP、EZH1和ZNF148为互不相交的基因突变,仅在29.2%的良性结节中出现,在配对的PTC肿瘤组织中不发生。扩大样本到259个良性结节中验证,25.8%的结节含有这3种基因突变。虽然这3个基因参与肿瘤相关的细胞生物学行为,发明人在甲状腺细胞系中做了功能实验,结果发现这3个基因仅促进增殖,但不影响侵袭功能。以上发现提示,这3个基因突变参与良性甲状腺结节形成,但并不导致其向肿瘤转化。目前甲状腺结节的基因突变检测仅包含甲状腺癌转换相关基因,为“纳入”检测;而发明人发现了SPOP,EZH1和ZNF148这3个良性结节相关基因,提供“排除”信息,在基因突变检测中有重要诊断意义。
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
序列表
<110> 宁, 光
<120> 良性甲状腺结节特异基因
<130> P2016-0836
<160> 16
<170> PatentIn version 3.5
<210> 1
<211> 3585
<212> DNA
<213> 智人(Homo sapiens)
<400> 1
gaggaggccg cgcggggtgg ggtctggcgg tacgcgctgg ctgcgtcgac gtgctgacgc 60
catgacgccc cggctggtgt gtgtcggtgt gtatgtgtgt gtgtgagtgt gcgcgctccg 120
agtgtgtgtg tatttgtgta tcggcggtcc cgcaggtccc ggatgttgcg gacagtatga 180
ggcaagcgca gggggacggg gaccagcagc tgtcgccgcc gctctcaggt gagtgggggg 240
aggagagtcg aggtttcttt tttccttttt tttttgagat cgagtcttgc tctgtcaccc 300
aggctggagt gcagtggcgc gatctcagct cactgccacc tttgcctcct gggttcaagc 360
gattcttctg cctcagcctc ccgagtagct gggattacag gtgagtgcca ccatgcctgg 420
ctaattttct tgcttcttgg atctgaccag ggtgaagagg gaacagaaat ctttgccccc 480
tgactttgga aatctcgttt aaccttcaaa ctggcgatgt caagggttcc aagtcctcca 540
cctccggcag aaatgtcgag tggccccgta gctgagagtt ggtgctacac acaggtaagt 600
tgaagttttc agcctgtgat tgcttcctgt ttttctatca acagatcaag gtagtgaaat 660
tctcctacat gtggaccatc aataacttta gcttttgccg ggaggaaatg ggtgaagtca 720
ttaaaagttc tacattttca tcaggagcaa atgataaact gaaatggtga ggaagaatac 780
gtctaactgt attttttttc tatctgtttt ggacaggtgt ttgcgagtaa accccaaagg 840
gttagatgaa gaaagcaaag attacctgtc actttacctg ttactggtca gctgtccaaa 900
gagtgaagtt cgggcaaaat tcaaattctc catcctgaat gccaagggag aagaaaccaa 960
agctatgggt aaatgttctc ctctttgttc aacatgactt tttttttccc caccccagag 1020
agtcaacggg catataggtt tgtgcaaggc aaagactggg gattcaagaa attcatccgt 1080
agagattttc ttttggatga ggccaacggg cttctccctg atgacaagct taccctcttc 1140
tgcgaggtga gtccttgtat tctgctgaga cgcttgtgtt tccttgtctt tcacaggtga 1200
gtgttgtgca agattctgtc aacatttctg gccagaatac catgaacatg gtaaaggttc 1260
ctgagtgccg gctggcagat gagttaggag gactgtggga gaattcccgg ttcacagact 1320
gctgcttgtg tgttgccggc caggaattcc aggctcacaa ggctatctta gcaggttggt 1380
atttattcat gaggaatttt gcttgtttct ctttgacttt gtagctcgtt ctccggtttt 1440
tagtgccatg tttgaacatg aaatggagga gagcaaaaag gtatgtaaca agatgaagac 1500
atgtcctcat attcagtttt tctggcatag aatcgagttg aaatcaatga tgtggagcct 1560
gaagttttta aggaaatgat gtgcttcatt tacacgggga aggctccaaa cctcgacaaa 1620
atggctgatg atttgctggc agctgctgac aaggtaagat aagaatagaa aaataatctg 1680
acagcagtgc ttgtgtttta cagtatgccc tggagcgctt aaaggtcatg tgtgaggatg 1740
ccctctgcag taacctgtcc gtggagaacg ctgcagaaat tctcatcctg gccgacctcc 1800
acagtgcaga tcagttgaaa actcaggcag tggatttcat caactagtga gttggcatct 1860
tcaaagttct tacccatttc tccacatttc tcctagtcat gcttcggatg tcttggagac 1920
ctctgggtgg aagtcaatgg tggtgtcaca tccccacttg gtggctgagg cataccgctc 1980
tctggcttca gcacagtgcc cttttctggg acccccacgc aaacgcctga agcaatccta 2040
agatcctgct tgttgtaaga ctccgtttaa tttccagaag cagcagccac tgttgctgcc 2100
actgaccacc aggtagacag cgcaatctgt ggagctttta ctctgttgtg aggggaagag 2160
actgcattgt ggccccagac ttttaaaaca gcactaaata acttggggga aacgggggga 2220
gggaaaatga aatgaaaacc ctgttgctgc gtcactgtgt tccctttggc ctggctgagt 2280
ttgatactgt ggggattcag tttaggcgct ggcccgagga tatcccagcg gtggtacttc 2340
ggagacacct gtctgcatct gactgagcag aacaaatcgt caggtgcctg gagcaaaaag 2400
gaaaaaaaaa aaagaaagga cattgagttt taacagaagg gaaaaggaaa gaagaaaaga 2460
tttttgcaga atttctcaaa aatcagtttg tggattccag tagtatttat attgagagaa 2520
acaaatttta gtccttctaa ctgtgctaaa acttggatat ttgtgaaaac tccttaccac 2580
catacaagca tcagaagagc tctcttgttg ttagcactta ttgtttgcaa gaacagaata 2640
catcctttta tccttttatg aaaaatgaca agtgaaggca aaaggggaag gttatttgat 2700
ctggaagatg agtgttctga tgtggtggct tttgcaaaaa tctttattgg tgttgaaaac 2760
tggaaaaaat aactcatcca gaattcatat tgtcttgaca agaactatgg ttctctgttt 2820
ttagatattg tggaaaatgt ttttgggcat ttttctctga ttttatttct tctcccccac 2880
ccctttttct aaaaaacaaa caaaaaaaaa aacacacaaa acaaaaacag aacaaaagaa 2940
gagagaagga aattttatca attaaaaatg ctgtgtgata aaatcccagc ccagattgct 3000
cagctgtttg tacctgactt gccgcctgca taggagccag ttctgttcct tctgactagc 3060
ccctcttcct ccaggggaga acttccaaat gttaattttt ttttttttga aaatataaat 3120
aattactatt ttgtactgtg tggtatctct ggtcttttgt ttcactcacc tgccttgtct 3180
cttgggtctg agtcccttgc ttaagggatt ttgaagtcct agttttcagc ttgcagagat 3240
tatgtctgaa atgcctaatg agtcgcaggg atttgttgag actccgtaat ctcaagttct 3300
ctttgtgagc tatcagcatc tgccagtctc ttgtcctccc tgagtatctc acagtccata 3360
tcctgatgag ggatcaggcc cctacctctg ccaaggcaag taatggtagt gggcttttaa 3420
actgcccccc gtatgtttta agacctaatc cccacctccc ttcttctaac taaatataaa 3480
aagatccagg ggacataaat gtggagatta aataaaggga aattattgtc tctaactggt 3540
tctgtcattg acttgatgtg tttccagaaa agctaatact ggagc 3585
<210> 2
<211> 374
<212> PRT
<213> 智人(Homo sapiens)
<400> 2
Met Ser Arg Val Pro Ser Pro Pro Pro Pro Ala Glu Met Ser Ser Gly
1 5 10 15
Pro Val Ala Glu Ser Trp Cys Tyr Thr Gln Ile Lys Val Val Lys Phe
20 25 30
Ser Tyr Met Trp Thr Ile Asn Asn Phe Ser Phe Cys Arg Glu Glu Met
35 40 45
Gly Glu Val Ile Lys Ser Ser Thr Phe Ser Ser Gly Ala Asn Asp Lys
50 55 60
Leu Lys Trp Cys Leu Arg Val Asn Pro Lys Gly Leu Asp Glu Glu Ser
65 70 75 80
Lys Asp Tyr Leu Ser Leu Tyr Leu Leu Leu Val Ser Cys Pro Lys Ser
85 90 95
Glu Val Arg Ala Lys Phe Lys Phe Ser Ile Leu Asn Ala Lys Gly Glu
100 105 110
Glu Thr Lys Ala Met Glu Ser Gln Arg Ala Tyr Arg Phe Val Gln Gly
115 120 125
Lys Asp Trp Gly Phe Lys Lys Phe Ile Arg Arg Asp Phe Leu Leu Asp
130 135 140
Glu Ala Asn Gly Leu Leu Pro Asp Asp Lys Leu Thr Leu Phe Cys Glu
145 150 155 160
Val Ser Val Val Gln Asp Ser Val Asn Ile Ser Gly Gln Asn Thr Met
165 170 175
Asn Met Val Lys Val Pro Glu Cys Arg Leu Ala Asp Glu Leu Gly Gly
180 185 190
Leu Trp Glu Asn Ser Arg Phe Thr Asp Cys Cys Leu Cys Val Ala Gly
195 200 205
Gln Glu Phe Gln Ala His Lys Ala Ile Leu Ala Ala Arg Ser Pro Val
210 215 220
Phe Ser Ala Met Phe Glu His Glu Met Glu Glu Ser Lys Lys Asn Arg
225 230 235 240
Val Glu Ile Asn Asp Val Glu Pro Glu Val Phe Lys Glu Met Met Cys
245 250 255
Phe Ile Tyr Thr Gly Lys Ala Pro Asn Leu Asp Lys Met Ala Asp Asp
260 265 270
Leu Leu Ala Ala Ala Asp Lys Tyr Ala Leu Glu Arg Leu Lys Val Met
275 280 285
Cys Glu Asp Ala Leu Cys Ser Asn Leu Ser Val Glu Asn Ala Ala Glu
290 295 300
Ile Leu Ile Leu Ala Asp Leu His Ser Ala Asp Gln Leu Lys Thr Gln
305 310 315 320
Ala Val Asp Phe Ile Asn Tyr His Ala Ser Asp Val Leu Glu Thr Ser
325 330 335
Gly Trp Lys Ser Met Val Val Ser His Pro His Leu Val Ala Glu Ala
340 345 350
Tyr Arg Ser Leu Ala Ser Ala Gln Cys Pro Phe Leu Gly Pro Pro Arg
355 360 365
Lys Arg Leu Lys Gln Ser
370
<210> 3
<211> 5723
<212> DNA
<213> 智人(Homo sapiens)
<400> 3
ggcacggcgc aggggtgggg ccgcggcgcg catgcgtcct agcagcggga cccgcggctc 60
gggatggagg gtgagtgagt aaacaagcct gggccccact gtctgttctc ttttgaaaag 120
ctggacacct gttctgctgt tgtgtcctgc cattctcctg aagaacagag gcacactgta 180
aaacccaaca cttccccttg cattctataa ggtaggtaaa gtatattaga atacattatt 240
tctcatctct gtctctctta gattacagca agatggaaat accaaatccc cctacctcca 300
aatgtatcac ttactggaaa agaaaagtga aatctgaata catgcgactt cgacaactta 360
aacggcttca ggcaaatatg ggtgcaaagg taaaaaataa ttcccaagtg aaagttaatc 420
ttttccatgg ctttgctagg ctttgtatgt ggcaaatttt gcaaaggttc aagaaaaaac 480
ccagatcctc aatgaagaat ggaagaagct tcgtgtccaa cctgttcagt caatgaagcc 540
tgtgagtgga cacccttttc tcaaaaaggt acttttggga gtttaagctc agtctccatg 600
tcattgctta tatttcagtg taccatagag agcattttcc cgggatttgc aagccaacat 660
atgttaatga ggtcactgaa cacagttgca ttggttccca tcatgtattc ctggtcccct 720
ctccaacaga actttatggt atgtattgaa agcactgtgg tggtaaatca catctggttt 780
ggtttcaggt agaagatgag acggttttgt gcaatattcc ctacatggga gatgaagtga 840
aagaagaaga tgagactttt attgaggagc tgatcaataa ctatgatggg aaagtccatg 900
gtgaagaagg tagtggtact gaactccttg gagacatctt tcgaatcctc atgtttcaga 960
gatgatccct ggatccgttc tgattagtga tgctgttttt ctggagttgg tcgatgccct 1020
gaatcagtac tcagatgagg aggaggaagg gcacaatgac acctcagatg gaaagcagga 1080
tgacagcaaa gaagatctgc cagtaacaag aaagagaaag cgacatgcta ttgaaggtac 1140
gtagcactgg ctcccttatt cgagcttttt atcatttcca attcaggcaa caaaaagagt 1200
tccaagaaac agttcccaaa tgacatgatc ttcagtgcaa ttgcctcaat gttccctgag 1260
aatggtgtcc cagatgacat gaaggagagg tagggaaagc tgtcccactt aggcctctta 1320
tctctctttt cttaaatagg tatcgagaac taacagagat gtcagacccc aatgcacttc 1380
cccctcagtg cacacccaac atcgatggcc ccaatgccaa gtctgtgcag cgggagcaat 1440
ctctgcactc cttccacaca cttttttgcc ggcgctgctt taaatacgac tgcttccttc 1500
accgtgagtg gggctactct gtttgaaaca acaagacagt ttttgttttc cagcttttca 1560
tgccacccct aatgtatata aacgcaagaa taaagaaatc aagattgaac cagaaccatg 1620
tggcacagac tgcttccttt tgctggtatg ttcttaagct gttctggcat cctgtctgta 1680
atgtgtccac tgcaggaagg agcaaaggag tatgccatgc tccacaaccc ccgctccaag 1740
tgctctggtc gtcgccggag aaggcaccac atagtcagtg cttcctgctc caatgcctca 1800
gcctctgctg tggctgagac taaagaagga gacagtgaca gggacacagg caatgactgg 1860
gcctccagtt cttcaggtac gatgaacaga aaatgaagac tattctgtta tttcttccct 1920
tctcagaggc taactctcgc tgtcagactc ccacaaaaca gaaggctagt ccagccccac 1980
ctcaactctg cgtagtggaa gcaccctcgg agcctgtgga atggactggg gctgaagaat 2040
ctctttttcg agtcttccat ggcacctact tcaacaactt ctgttcaata gccaggcttc 2100
tggggaccaa gacgtgcaag caggtaccat ctggaagcag cagaacaaca ggcccgttgg 2160
atttctcttc caggtctttc agtttgcagt caaagaatca cttatcctga agctgccaac 2220
agatgagctc atgaacccct cacagaagaa gaaaagaaag cacaggcaag aagggttgga 2280
caaagtgttt gacctgtcct tcctgtcttt ttcagattgt gggctgcaca ctgcaggaag 2340
attcagctga agaaaggtaa gttctaccag ggcattcttc acatcctcct ctgttttctt 2400
tcctagataa ctcttccaca caagtgtaca actaccaacc ctgcgaccac ccagaccgcc 2460
cctgtgacag cacctgcccc tgcatcatga ctcagaattt ctgtgagaag ttctgccagt 2520
gcaacccaga ctgtaagtgt gctacgtttt ctgtataaga cttacctgtc ttcccttccc 2580
aggtcagaat cgtttccctg gctgtcgctg taagacccag tgcaatacca agcaatgtcc 2640
ttgctatctg gcagtgcgag aatgtgaccc tgacctgtgt ctcacctgtg gggcctcaga 2700
gcactgggac tgcaaggtgg tttcctgtaa aaactgcagc atccagcgtg gacttaagaa 2760
ggtgaggcct ttcctcagga ccccactgag acttggcccc ctcttcccca gcacctgctg 2820
ctggccccct ctgatgtggc cggatggggc accttcataa aggagtctgt gcagaagaac 2880
gaattcattt ctgaatactg tggtgaggtg agtgctatag ttttggccca caatttgtta 2940
tttgtctatc tctctagctc atctctcagg atgaggctga tcgacgcgga aaggtctatg 3000
acaaatacat gtccagcttc ctcttcaacc tcaataatgg tatgaagtca ctttgtctca 3060
tcccgttttc cttgatttac tttatacaga ttttgtagtg gatgctactc ggaaaggaaa 3120
caaaattcga tttgcaaatc attcagtgaa tcccaactgt tatgccaaag gtgagtccca 3180
gtaacctggg aggtgagcct cgggtttatc ctgcttgcag tggtcatggt gaatggagac 3240
catcggattg ggatctttgc caagagggca attcaagctg gcgaagagct cttctttgat 3300
tacaggtgag gtgccagtaa tggtccttgg gttcctcttc cctgctctgg gacaggtaca 3360
gccaagctga tgctctcaag tacgtgggga tcgagaggga gaccgacgtc ctttagccct 3420
cccaggcccc acggcagcac ttatggtagc ggcactgtct tggctttcgt gctcacacca 3480
ctgctgctcg agtctcctgc actgtgtctc ccacactgag aaacccccca acccactccc 3540
tctgtagtga ggcctctgcc atgtccagag ggcacaaaac tgtctcaatg agaggggaga 3600
cagaggcagc tagggcttgg tctcccagga cagagagtta cagaaatggg agactgtttc 3660
tctggcctca gaagaagcga gcacaggctg gggtggatga cttatgcgtg atttcgtgtc 3720
ggctccccag gctgtggcct caggaatcaa cttaggcagt tcccaacaag cgctagcctg 3780
taattgtagc tttccacatc aagagtcctt atgttattgg gatgcaggca aacctctgtg 3840
gtcctaagac ctggagagga caggctaagt gaagtgtggt ccctggagcc tacaagtggt 3900
ctgggttaga ggcgagcctg gcaggcagca cagactgaac tcagaggtag acaggtcacc 3960
ttactacctc ctccctcgtg gcagggctca aactgaaaga gtgtgggttc taagtacagg 4020
cattcaaggc tgggggaagg aaagctacgc catccttcct tagccagaga gggagaacca 4080
gccagatgat agtagttaaa ctgctaagct tgggcccagg aggctttgag aaagccttct 4140
ctgtgtactc tggagataga tggagaagtg ttttcagatt cctgggaaca gacaccagtg 4200
ctccagctcc tccaaagttc tggcttagca gctgcaggca agcattatgc tgctattgaa 4260
gaagcattag gggtatgcct ggcaggtgtg agcatcctgg ctcgctggat ttgtgggtgt 4320
tttcaggcct tccattcccc atagaggcaa ggcccaatgg ccagtgttgc ttatcgcttc 4380
agggtaggtg ggcacaggct tggactagag aggagaaaga ttggtgtaat ctgctttcct 4440
gtctgtagtg cctgctgttt ggaaagggtg agttagaata tgttccaagg ttggtgaggg 4500
gctaaattgc acgcgtttag gctggcaccc cgtgtgcagg gcacactggc agagggtatc 4560
tgaagtggga gaagaagcag gtagaccacc tgtcccaggc tgtggtgcca ccctctctgg 4620
cattcatgca gagcaaagca ctttaaccat ttcttttaaa aggtctatag attggggtag 4680
agtttggcct aaggtctcta gggtccctgc ctaaatccca ctcctgaggg agggggaaga 4740
agagagggtg ggagattctc ctccagtcct gtctcatctc ctgggagagg cagacgagtg 4800
agtttcacac agaagaattt catgtgaatg gggccagcaa gagctgccct gtgtccatgg 4860
tgggtgtgcc gggctggctg ggaacaagga gcagtatgtt gagtagaaag ggtgtgggcg 4920
ggtatagatt ggcctgggag tgttacagta gggagcaggc ttctcccttc tttctgggac 4980
tcagagcccc gcttcttccc actccacttg ttgtcccatg aaggaagaag tggggttcct 5040
cctgacccag ctgcctctta cggtttggta tgggacatgc acacacactc acatgctctc 5100
actcaccaca ctggagggca cacacgtacc ccgcacccag caactcctga cagaaagctc 5160
ctcccaccca aatgggccag gccccagcat gatcctgaaa tctgcatccg ccgtggtttg 5220
tattcattgt gcatatcagg gataccctca agctggactg tgggttccaa attactcata 5280
gaggagaaaa ccagagaaag atgaagagga ggagttaggt ctatttgaaa tgccaggggc 5340
tcgctgtgag gaataggtga aaaaaaactt ttcaccagcc tttgagagac tagactgacc 5400
ccacccttcc ttcagtgagc agaatcactg tggtcagtct cctgtcccag cttcagttca 5460
tgaatactcc tgttcctcca gtttcccatc ctttgtccct gctgtccccc acttttaaag 5520
atgggtctca acccctcccc accacgtcat gatggatggg gcaaggtggt ggggactagg 5580
ggagcctggt atacatgcgg cttcattgcc aataaatttc atgcacttta aagtcctgtg 5640
gcttgtgacc tcttaataaa gtgttagaat ccattttggc aagttgtgta ctgtgtgctt 5700
tggggctgga aggatccagg gat 5723
<210> 4
<211> 747
<212> PRT
<213> 智人(Homo sapiens)
<400> 4
Met Glu Ile Pro Asn Pro Pro Thr Ser Lys Cys Ile Thr Tyr Trp Lys
1 5 10 15
Arg Lys Val Lys Ser Glu Tyr Met Arg Leu Arg Gln Leu Lys Arg Leu
20 25 30
Gln Ala Asn Met Gly Ala Lys Ala Leu Tyr Val Ala Asn Phe Ala Lys
35 40 45
Val Gln Glu Lys Thr Gln Ile Leu Asn Glu Glu Trp Lys Lys Leu Arg
50 55 60
Val Gln Pro Val Gln Ser Met Lys Pro Val Ser Gly His Pro Phe Leu
65 70 75 80
Lys Lys Cys Thr Ile Glu Ser Ile Phe Pro Gly Phe Ala Ser Gln His
85 90 95
Met Leu Met Arg Ser Leu Asn Thr Val Ala Leu Val Pro Ile Met Tyr
100 105 110
Ser Trp Ser Pro Leu Gln Gln Asn Phe Met Val Glu Asp Glu Thr Val
115 120 125
Leu Cys Asn Ile Pro Tyr Met Gly Asp Glu Val Lys Glu Glu Asp Glu
130 135 140
Thr Phe Ile Glu Glu Leu Ile Asn Asn Tyr Asp Gly Lys Val His Gly
145 150 155 160
Glu Glu Glu Met Ile Pro Gly Ser Val Leu Ile Ser Asp Ala Val Phe
165 170 175
Leu Glu Leu Val Asp Ala Leu Asn Gln Tyr Ser Asp Glu Glu Glu Glu
180 185 190
Gly His Asn Asp Thr Ser Asp Gly Lys Gln Asp Asp Ser Lys Glu Asp
195 200 205
Leu Pro Val Thr Arg Lys Arg Lys Arg His Ala Ile Glu Gly Asn Lys
210 215 220
Lys Ser Ser Lys Lys Gln Phe Pro Asn Asp Met Ile Phe Ser Ala Ile
225 230 235 240
Ala Ser Met Phe Pro Glu Asn Gly Val Pro Asp Asp Met Lys Glu Arg
245 250 255
Tyr Arg Glu Leu Thr Glu Met Ser Asp Pro Asn Ala Leu Pro Pro Gln
260 265 270
Cys Thr Pro Asn Ile Asp Gly Pro Asn Ala Lys Ser Val Gln Arg Glu
275 280 285
Gln Ser Leu His Ser Phe His Thr Leu Phe Cys Arg Arg Cys Phe Lys
290 295 300
Tyr Asp Cys Phe Leu His Pro Phe His Ala Thr Pro Asn Val Tyr Lys
305 310 315 320
Arg Lys Asn Lys Glu Ile Lys Ile Glu Pro Glu Pro Cys Gly Thr Asp
325 330 335
Cys Phe Leu Leu Leu Glu Gly Ala Lys Glu Tyr Ala Met Leu His Asn
340 345 350
Pro Arg Ser Lys Cys Ser Gly Arg Arg Arg Arg Arg His His Ile Val
355 360 365
Ser Ala Ser Cys Ser Asn Ala Ser Ala Ser Ala Val Ala Glu Thr Lys
370 375 380
Glu Gly Asp Ser Asp Arg Asp Thr Gly Asn Asp Trp Ala Ser Ser Ser
385 390 395 400
Ser Glu Ala Asn Ser Arg Cys Gln Thr Pro Thr Lys Gln Lys Ala Ser
405 410 415
Pro Ala Pro Pro Gln Leu Cys Val Val Glu Ala Pro Ser Glu Pro Val
420 425 430
Glu Trp Thr Gly Ala Glu Glu Ser Leu Phe Arg Val Phe His Gly Thr
435 440 445
Tyr Phe Asn Asn Phe Cys Ser Ile Ala Arg Leu Leu Gly Thr Lys Thr
450 455 460
Cys Lys Gln Val Phe Gln Phe Ala Val Lys Glu Ser Leu Ile Leu Lys
465 470 475 480
Leu Pro Thr Asp Glu Leu Met Asn Pro Ser Gln Lys Lys Lys Arg Lys
485 490 495
His Arg Leu Trp Ala Ala His Cys Arg Lys Ile Gln Leu Lys Lys Asp
500 505 510
Asn Ser Ser Thr Gln Val Tyr Asn Tyr Gln Pro Cys Asp His Pro Asp
515 520 525
Arg Pro Cys Asp Ser Thr Cys Pro Cys Ile Met Thr Gln Asn Phe Cys
530 535 540
Glu Lys Phe Cys Gln Cys Asn Pro Asp Cys Gln Asn Arg Phe Pro Gly
545 550 555 560
Cys Arg Cys Lys Thr Gln Cys Asn Thr Lys Gln Cys Pro Cys Tyr Leu
565 570 575
Ala Val Arg Glu Cys Asp Pro Asp Leu Cys Leu Thr Cys Gly Ala Ser
580 585 590
Glu His Trp Asp Cys Lys Val Val Ser Cys Lys Asn Cys Ser Ile Gln
595 600 605
Arg Gly Leu Lys Lys His Leu Leu Leu Ala Pro Ser Asp Val Ala Gly
610 615 620
Trp Gly Thr Phe Ile Lys Glu Ser Val Gln Lys Asn Glu Phe Ile Ser
625 630 635 640
Glu Tyr Cys Gly Glu Leu Ile Ser Gln Asp Glu Ala Asp Arg Arg Gly
645 650 655
Lys Val Tyr Asp Lys Tyr Met Ser Ser Phe Leu Phe Asn Leu Asn Asn
660 665 670
Asp Phe Val Val Asp Ala Thr Arg Lys Gly Asn Lys Ile Arg Phe Ala
675 680 685
Asn His Ser Val Asn Pro Asn Cys Tyr Ala Lys Val Val Met Val Asn
690 695 700
Gly Asp His Arg Ile Gly Ile Phe Ala Lys Arg Ala Ile Gln Ala Gly
705 710 715 720
Glu Glu Leu Phe Phe Asp Tyr Arg Tyr Ser Gln Ala Asp Ala Leu Lys
725 730 735
Tyr Val Gly Ile Glu Arg Glu Thr Asp Val Leu
740 745
<210> 5
<211> 10151
<212> DNA
<213> 智人(Homo sapiens)
<400> 5
agcgcttccc gtgtgcgggg cttcccacaa tgcaccgggc cggcagtggc ggcgaccgcg 60
gcggcgctct agctgcggca tgtctgcgtc tctactgctc tgggaggagg aagagaagga 120
ggaagaggag gaggaggagg agggggagga agaggagaaa ggcgcagggg tgggagctgt 180
tgccgaagct gccacagcaa aagttctccc ccctcccccc ttcccctcct ctcaaggccc 240
ctagaaaggt tggagctgcc gccgcctgca gtcggtgacc gcgcgactcg gcgcccgccc 300
gcggtaaagc gctcggcctg gcaggcccaa cctgtatttg tgtacttttg taggatagag 360
ggaggaatca gcagcttgga aattcaagca cgtgatctgg cgggatgggc gtttgcctaa 420
cgtatttaat ggaggtaatt cagcattctt tgagtcaatt tgttgtgtgt gtgttttatt 480
gtaggaatcg gatggcataa gtgattaagg tggtattgag gatttctgaa gcctatgaaa 540
ggtagaaact caaccatgat ttctttttca actctacagc attcctttcc ttgaagtctt 600
cgtttttacc ttagtctcgg gtaattttaa tacttatttt tcatatttgt tgccaaactt 660
ggttttctag gcagttatac ttaagcatga acattgacga caaactggaa ggattgtttc 720
ttaaatgtgg cggcatagac gaaatgcagt cttccaggac aatggttgta atgggtggag 780
tgtctggcca gtctactgtg tctggagagc tacaggattc agtacttcaa gatcgaagta 840
tgcctcacca ggagatcctt gctgcagatg aagtgttaca agaaagtgaa atgagacaac 900
aggatatgat atcacatgat gaactcatgg tccatgagga gacagtgaaa aatgatgaag 960
agcagatgga aacacatgaa agacttcctc aaggactaca gtatgcactt aatgtccctg 1020
taagtaattc ctttataaga tattaattgg cttttctttt tttaaacaga taagcgtaaa 1080
gcaggaaatt acttttactg atgtatctga gcaactgatg agagacaaaa aacaaatcag 1140
agagccagta gacttacaga aaaagaagaa gcggaaacaa cgttctcccg caaaagtaag 1200
acaatgtatt aaggtggtaa ttttgccttt ttttttttga actagatcct tacaataaat 1260
gaggatggat cacttggttt gaaaacccct aaatctcacg tttgtgagca ctgcaatgct 1320
gcctttagaa cgaactatca cttacagaga catgtcttca ttcatacagg tatttcttga 1380
attaaaatgg gctttttgtg gatgtgaaat tattttaagg tgaaaaacca tttcaatgta 1440
gtcaatgtga catgcgtttc atacagaagt acctgcttca gagacatgag aagattcata 1500
ctggtgagtg ttaaccaccc ttactaggtt aaactttcta tattatgtgc taggtgaaaa 1560
accatttcgc tgtgatgaat gtggtatgag attcatacaa aaatatcata tggaaaggca 1620
taagagaact catagtggag aaaaacctta ccagtgtgaa tactgtttac aggtaagaga 1680
gatggcttga aattcttcac taccatcctc tgaattcaac agtatttttc cagaacagat 1740
cgtgtattga aacataaacg tatgtgccat gaaaatcatg acaaaaaact aaatagatgt 1800
gccatcaaag gtggccttct gacatctgag gaagattctg gcttttctac atcaccaaaa 1860
gacaactcac tgccaaaaaa gaaaaggcag aaaacggaga aaaaatcatc tggaatggac 1920
aaagagagtg ctttggacaa atctgacctg aaaaaagaca aaaatgatta cttgcctctt 1980
tattcttcaa gtactaaagt aaaagatgag tatatggttg cagaatatgc tgttgaaatg 2040
ccacattcgt cagttggggg ctcgcattta gaagatgcgt caggagaaat acacccacct 2100
aagttagttc tcaaaaaaat taatagtaag agaagtctga aacagccact ggagcaaaat 2160
caaacaattt cacctttatc cacatatgaa gagagcaaag tttcaaagta tgcttttgaa 2220
cttgtggata aacaggcttt actggactca gaaggcaatg ctgacattga tcaggttgat 2280
aatttgcagg aggggcccag taaacctgtg catagtagta ctaattatga tgatgccatg 2340
cagtttttga agaagaagcg gtatcttcaa gcagcaagta acaacagcag ggaatatgcg 2400
ctgaatgtgg gtaccatagc ttctcagcct tctgtaacac aagcagctgt ggcaagtgtc 2460
attgatgaaa gtaccacggc atccatatta gagtcacagg cactgaatgt ggagattaag 2520
agtaatcatg acaaaaatgt tattccagat gaggtactgc agactctgtt ggatcattat 2580
tcccacaaag ctaatggaca gcatgagata tccttcagtg ttgcagatac tgaagtgact 2640
tctagcatat caataaattc ttcagaagta ccagaggtca ccccgtcaga gaatgttgga 2700
tcaagctccc aagcatcctc atcagataaa gccaacatgt tgcaggaata ctccaagttt 2760
ctgcagcagg ctttggacag aactagccaa aatgatgcct atttgaatag cccgagcctt 2820
aactttgtga ctgataacca gaccctccca aatcagccag cattctcttc catagacaag 2880
caggtctatg ccaccatgcc catcaatagc tttcgatcag gaatgaattc tccactaaga 2940
acaactccag ataagtccca ctttggacta atagttggtg attcacagca ctcatttccc 3000
ttttcaggtg atgagacaaa ccatgcttct gccacatcaa cacaggactt tctggatcaa 3060
gtgacttctc agaagaaagc tgaggcccag cctgtccacc aagcttacca aatgagctcc 3120
tttgaacagc ccttccgtgc tccctatcat ggatcaagag ctggaatagc tactcaattt 3180
agcactgcca atggacaggt gaaccttcgg ggaccaggga caagtgctga attttcagaa 3240
tttcccttgg tgaatgtaaa tgataataga gctgggatga catcttcacc tgatgccaca 3300
actggccaga cttttggcta aaaaaaaaaa aaaagtgtaa ataatactgg cactttagaa 3360
cagattaatc aagagtgggg ttactctgtg taaatggagt gctgtacaga tttaagagca 3420
atgcgtaata acaagttaag ctgatatgaa tagcaagata atccaataac tgcatttcgt 3480
ttggttagtc agcattcttt gaactgcctt acatgttgtc acctttatag aagcaatgca 3540
ttacttgttt tagatcagaa acttgctatt ccacccacac caagttaaaa aggaaaaaaa 3600
aaagactttc gcacaattgt ttcctaactg ataacattgt acattcttag gagattagta 3660
attgtgtgaa atttactcat actgtttcta agtttttcag catagtcatt gcacttcagc 3720
agggaatctg agtatacttt acagacagag tgaacttaaa agtttaatgt caagagatta 3780
tggcttaaat aaattagtgt gtcctatagg gggaaaaaaa ccaagaaacc accttttaaa 3840
aagaatgata tgccatatac ccttgatttt cattttgcat tatattgacg tgtttttttg 3900
aaggaaaaaa agtaataaaa atctgatagt ctaagactcc actatttaaa agcctaatta 3960
ctttaaaaat atgcatactt tcagaacttt taccaaaaca cacaactgtt gaagcagtca 4020
cttctctatg gaagtatgca tattggtgtc agtttctttg tacagttgta cttagatatt 4080
ttttatgatt tttcatgtgc aggtatcaag gttttgaagt tttagtaaaa gaaattctgt 4140
agattacatt cccaagaaca taatgcttac acaaaatgta tattccacgt tttaaagctt 4200
aattgtattt tactttacat atacacttca gttaacatag agcacttaga atctatttgg 4260
tatttttgat ttctcaaagt aaaaaaaaaa ttagattttt aggtttgata tggttgtgtc 4320
ataatcatct cgtaattgac aattttaact tttggcaata aaaggaaatt gggatatctt 4380
tggaactgta aaacctggtt taatcttttt ctttctagac tcttgataga ttggataatt 4440
aaacagtatc cagagaaact aaagaaatgg gcattttaat tgcatatttt atcttgagtt 4500
actttttaat gaacactgct cattacaact ttacaaacca aaagtgttta ctaattccag 4560
taactaccat ttctttttca gctagatgag tgatcggaaa atttttgttg catttcaaaa 4620
tctaaataaa ctacagactt tatccttata ccatgaatgt ttttttttaa tactctgtct 4680
taaaataata cagcatggta caataaatag tgcttttatg tatatataca cacacacact 4740
tttctgaaga atgatggttt gagttatgcg ttgggcagtt ttgatttttg gaagttatat 4800
tagttattga ctctttgtta caactttttc atttttacat tttaaatttt ctgccatcgt 4860
tgtcacaatg cacatcctga tatagcacca gtgaaaatct aaaattaata cccttggaaa 4920
atgaaaatat tcttaatttc cattttgact cttatactgg ccctatagct ctgcagtctt 4980
tgtttcaata tagaatatgt tatccattta aattattttt tcttttattt aatgttatcc 5040
caagactgtt ctcataaaga aagggaagaa ataactatcc acccttaaca tccttcattt 5100
attttgaata tattggtgtt tttatgataa ggaatataaa ttatatttaa tgtggtttcc 5160
tgtatacttt ggttattaag ttttgcttga aatagtagtt ttcccgtttg acagctttct 5220
ttgctgccaa agttttcaag aatttaagac ttctttgaag taaatattta agttctgcca 5280
ttattgactc ttaagattgt gtgtgttgtg ttgtgcatta cataattaca aaaaggcttc 5340
attcaggtga tacgttaaaa atggaactgt gctcacccta aataggcatt ggtatttttc 5400
tcttttggtg agagtaggca tttatttctt gagttgtttt ggagcctgat caaaaatttt 5460
gttcatggag aacttgatgc aattttgata cagtggagag gtttttttcg gttgttttaa 5520
catcaccagc atagttttta gaatgtgact cttgctgagc atttagggtg agcttgggaa 5580
ggaaggcctt tgaaaatggt agttatgcaa gcagactttc aggtgttgca ttcctgtttt 5640
caacacattt ctttaaatct acataatggc agacttttct accaggttat aagcagtttt 5700
tagataagtg atactcagcc agcataactt attgacttac catttacgta tagtcatcac 5760
tctcttactg tgaaattcca aatgcctacc agagttacct tgttctatca taatatgaca 5820
aacatctcaa cagttttgga tttccccact ttggttcaga aggttattta atttctatct 5880
gggcattaat ggagaaaata agtagccttg tgtgctgctt cagattgaaa catggaggat 5940
atgagatatt cttctgcaat tcatgtttct catttctcaa agtgagcaca ttgttctata 6000
aaaacatgct ggtacaccct taaacttttg atcaatctga gtgaggtgtg cttttcctct 6060
tgggacctac tcacgtttga agattggaaa catcacgtta ggcgaggcag tatctcttga 6120
acatcttcta aagggttttt taaaacctta ttctcacata tttcatttgt cttgaatatt 6180
taagtggctc ttaaacgttt tgggtctaca tgcaaatgtg gtacttaaca aggtaggaat 6240
ccatcttctt agctctggct gagggtgcca gccatcggtc aggtcatttt tatctcaaga 6300
ggcagaaggc agttatgtca agaattgtgc tcagggcagg atttcgtttc cacagaggag 6360
agacacttgc agagtgccag ctaggttaga tcttttgccg cttctttcat ttgattaatt 6420
tgggttttta aagggctgtt taaaaaaaaa aaaaaaaggc cgggaaactt taaaagtagg 6480
cattactgta gtactgcatt tcttagaaca ttttaaacta gaactcattt ttttttcaca 6540
gtatatttac ttgaagaagc actataataa tcattgagaa gtattttgag tctgaaattt 6600
aatttaattt tccgtttcaa attgctttat ttcagggaaa taattttcca gttgttttgc 6660
tatattctgc aaataaaaac cgtgtttcct tttttcactt aaactttggt aggaaacaaa 6720
ctaaagcaga caaacatttc ttgttatgtt tgttgctttc tttaatccaa tggataaaaa 6780
agtaaaaccc tgtaaacatt attttatttt tttatgcaat accatgctgt aaatatggtt 6840
catcaaataa ggatgtacct atgattgaat ctttaattct gcacagttag agtttatata 6900
taaacgtgtc ttgacaatca aggactttta tgtgagtctt cctttatgat gtttattaat 6960
gttatgcatt ccatttgttt tgaagtgagt accaatgtgc taatttgtat tgtctgaaag 7020
tatgtaatgt ttttacagct tgtttttaag aatctgtaaa tatgtacaaa caaatcacag 7080
tactgcttta tgttagaagg catatgatgt tgtactgtat gtaagcaata atacatagca 7140
gtgctaactt tacaagtagc atcaggaaag ttctaaaaac atttcagagt tattaattat 7200
ccttatttca tttaataatg attatcttta atcagttttt ataagcaaat tccattgttc 7260
ctcctattgg aacgtaacac tgtttacaca gcataattga agttgcaggg gagacaggct 7320
aaatctgact tcatctgtac tcactttcac taagcattga atggccttac cactcttctg 7380
caagatggag gaagaccgca aaacttagtg cccatcacac tgaaggaagg gatgtggttt 7440
tttttcctgc ttctgtactg ctacctaact ttgtgatttg ctttggattt taatatttgt 7500
ttctgtttta gattcaagcc cgtaagtttt gaggtgactt cagctccatt gtgaaataga 7560
tagttctctt catatttcat aactacattt caataattct aaactttcta cattgatttt 7620
tagatactta tttttcaagc ttggtttctc agctgatcag atgaatttat tcaacttcaa 7680
tacaaagaaa gacaaaccta ttatagtttc aagtgagtag atattatact gtacaggaca 7740
gctatttgaa cacacacatc actgctttag aaataaaacc gccaatttat aaatgtatat 7800
gacctacatt ttataggaaa aaatgttttt aaatgctagt catttatata atgtgctttg 7860
aaggatttgc tagtccactt ctgtcacttt ttagtacact ggtatctttt atatgtaatg 7920
tatgcttttt attattgtag caaagcattt cagtagaaag aattttgcaa caatatgggg 7980
gaaatttttc attgttggat ttgaattata ctggatttta tctgtgtagt cttacttgtc 8040
tttattttaa tgctgtctga agggaacttg gtatccaaat aaagcaggta acctcatttt 8100
acttcaaggg catactgtgt agtgctgaat ttaatctgaa aatctgatga ttttgaaaag 8160
aaaaacaagt ttataaacat tgtacagaag aaattaaatg tgtgtgatgg aaatcctgat 8220
ggtggagcac gttgaatttt ctgatatata gtgttatttt cctgggatcc cctatgcctt 8280
ctttgtattt caactaataa aggaaaaacc ctgtcattaa aactggtaag ataataggat 8340
attctgatta tacagtatta ctattcctat cccattttct gaccttttct caatcactgt 8400
aaatttttat tttctatttc ctattgataa ttaaatatgt acataatata gacactgttg 8460
tatagaacta aatgaattgg gttgctatgc ttgagtgggt agtgaaatgg aaatatttga 8520
tgaatactga gagttcctaa aatgctagag caaatttccg agggaaaggg gggcatcgtg 8580
tgtcttggga aggttgcagc aggttgtttc ttcaactccc taagaaatca ttgggaagga 8640
ctcaactgca aactcgggat cagatacaaa atgggtcttt ccttcccctc tcccccaaaa 8700
aataggagca ctaaatttta aaatctactc aggtgacagt tgctttgcaa tgaaacttat 8760
cacattgaaa ttttcagtgt taaataaaaa gagatttgtg atatttttaa atataaactt 8820
ttacatcagt agtcagcagc ctgacaattg aaatttggta agtcgatata ttttaaaata 8880
ttttgctctc caaatagaat tgtttttaaa caattgggag gttttttgtt tctttaaata 8940
tgttttaatt gtcattgtaa aaacaaaatc ttgcttgacc ctatattatg ccatgaatga 9000
attgctgagc ctttataata cagtgacagc ttgtttcatg catagtcatg gaacatagag 9060
atgttcttta aactgaccta ttgataagag gtttaatgag tttcacggct ttcaacacta 9120
ttgtcatata gttatctttg ccatttggag tttataaaac cattttatgt attgtgatac 9180
taaaggaagt tgttttgctt tactttaaat tgaattatta gactaatatt tgcaaattct 9240
gcattttaaa tgtggacact ggctgtttga aaaataaaat atagaataca gttttatgga 9300
taattttcga gctgaatttt tcacaatatt ctgaaccaaa taacgaatgg taaatatgca 9360
aaaatcatgg tgcatagata taaccgtaaa gagaaaagaa tttctgtgtg gaattaacag 9420
ttacacaaat tgggtaacaa ttatcagggc ctttattata gctttatgtg gaatgttatt 9480
ctaaaatgca agagtcaaat gttactgtca ttgaatattt tagacttgaa acgtgtttat 9540
catagagcga agaaaatatg tgttcttttc tttacagata agactctgtt aacccactgt 9600
cagcatacgt gggatttctt ttcttttttc tttcattagt ggagatttgt tttcatccat 9660
ctaccacctt gccagtaccc tagcttgtga ccagcgggat gcattgtaag aaagttgtct 9720
gtggttagga gtgcagtctg ggtccatgga acaaatttaa actaattggc cctcgcaatg 9780
atcagtccta ggaccctggc cttattatta gcatggtgct ttaaccaatt gtacataata 9840
ataccactga tagtctacta atgcatttcc tagatcccag tttttcttga atgattagga 9900
atggtgggga gaggggaggg gagatattct acatgatact tctccaatct tctaaagatt 9960
ataagaaaaa ataaaaaatt gaagtcactt gaattaatgt gttgtcattg agtcttactc 10020
gacaatttat catgcacaaa gtgattatga agattttcct gattatatgt ttggattgaa 10080
tttaaaaatt ttttttttca gaatgctggc tgttctgttt tatttcttct ctggtgaacc 10140
tgataggata t 10151
<210> 6
<211> 794
<212> PRT
<213> 智人(Homo sapiens)
<400> 6
Met Asn Ile Asp Asp Lys Leu Glu Gly Leu Phe Leu Lys Cys Gly Gly
1 5 10 15
Ile Asp Glu Met Gln Ser Ser Arg Thr Met Val Val Met Gly Gly Val
20 25 30
Ser Gly Gln Ser Thr Val Ser Gly Glu Leu Gln Asp Ser Val Leu Gln
35 40 45
Asp Arg Ser Met Pro His Gln Glu Ile Leu Ala Ala Asp Glu Val Leu
50 55 60
Gln Glu Ser Glu Met Arg Gln Gln Asp Met Ile Ser His Asp Glu Leu
65 70 75 80
Met Val His Glu Glu Thr Val Lys Asn Asp Glu Glu Gln Met Glu Thr
85 90 95
His Glu Arg Leu Pro Gln Gly Leu Gln Tyr Ala Leu Asn Val Pro Ile
100 105 110
Ser Val Lys Gln Glu Ile Thr Phe Thr Asp Val Ser Glu Gln Leu Met
115 120 125
Arg Asp Lys Lys Gln Ile Arg Glu Pro Val Asp Leu Gln Lys Lys Lys
130 135 140
Lys Arg Lys Gln Arg Ser Pro Ala Lys Ile Leu Thr Ile Asn Glu Asp
145 150 155 160
Gly Ser Leu Gly Leu Lys Thr Pro Lys Ser His Val Cys Glu His Cys
165 170 175
Asn Ala Ala Phe Arg Thr Asn Tyr His Leu Gln Arg His Val Phe Ile
180 185 190
His Thr Gly Glu Lys Pro Phe Gln Cys Ser Gln Cys Asp Met Arg Phe
195 200 205
Ile Gln Lys Tyr Leu Leu Gln Arg His Glu Lys Ile His Thr Gly Glu
210 215 220
Lys Pro Phe Arg Cys Asp Glu Cys Gly Met Arg Phe Ile Gln Lys Tyr
225 230 235 240
His Met Glu Arg His Lys Arg Thr His Ser Gly Glu Lys Pro Tyr Gln
245 250 255
Cys Glu Tyr Cys Leu Gln Tyr Phe Ser Arg Thr Asp Arg Val Leu Lys
260 265 270
His Lys Arg Met Cys His Glu Asn His Asp Lys Lys Leu Asn Arg Cys
275 280 285
Ala Ile Lys Gly Gly Leu Leu Thr Ser Glu Glu Asp Ser Gly Phe Ser
290 295 300
Thr Ser Pro Lys Asp Asn Ser Leu Pro Lys Lys Lys Arg Gln Lys Thr
305 310 315 320
Glu Lys Lys Ser Ser Gly Met Asp Lys Glu Ser Ala Leu Asp Lys Ser
325 330 335
Asp Leu Lys Lys Asp Lys Asn Asp Tyr Leu Pro Leu Tyr Ser Ser Ser
340 345 350
Thr Lys Val Lys Asp Glu Tyr Met Val Ala Glu Tyr Ala Val Glu Met
355 360 365
Pro His Ser Ser Val Gly Gly Ser His Leu Glu Asp Ala Ser Gly Glu
370 375 380
Ile His Pro Pro Lys Leu Val Leu Lys Lys Ile Asn Ser Lys Arg Ser
385 390 395 400
Leu Lys Gln Pro Leu Glu Gln Asn Gln Thr Ile Ser Pro Leu Ser Thr
405 410 415
Tyr Glu Glu Ser Lys Val Ser Lys Tyr Ala Phe Glu Leu Val Asp Lys
420 425 430
Gln Ala Leu Leu Asp Ser Glu Gly Asn Ala Asp Ile Asp Gln Val Asp
435 440 445
Asn Leu Gln Glu Gly Pro Ser Lys Pro Val His Ser Ser Thr Asn Tyr
450 455 460
Asp Asp Ala Met Gln Phe Leu Lys Lys Lys Arg Tyr Leu Gln Ala Ala
465 470 475 480
Ser Asn Asn Ser Arg Glu Tyr Ala Leu Asn Val Gly Thr Ile Ala Ser
485 490 495
Gln Pro Ser Val Thr Gln Ala Ala Val Ala Ser Val Ile Asp Glu Ser
500 505 510
Thr Thr Ala Ser Ile Leu Glu Ser Gln Ala Leu Asn Val Glu Ile Lys
515 520 525
Ser Asn His Asp Lys Asn Val Ile Pro Asp Glu Val Leu Gln Thr Leu
530 535 540
Leu Asp His Tyr Ser His Lys Ala Asn Gly Gln His Glu Ile Ser Phe
545 550 555 560
Ser Val Ala Asp Thr Glu Val Thr Ser Ser Ile Ser Ile Asn Ser Ser
565 570 575
Glu Val Pro Glu Val Thr Pro Ser Glu Asn Val Gly Ser Ser Ser Gln
580 585 590
Ala Ser Ser Ser Asp Lys Ala Asn Met Leu Gln Glu Tyr Ser Lys Phe
595 600 605
Leu Gln Gln Ala Leu Asp Arg Thr Ser Gln Asn Asp Ala Tyr Leu Asn
610 615 620
Ser Pro Ser Leu Asn Phe Val Thr Asp Asn Gln Thr Leu Pro Asn Gln
625 630 635 640
Pro Ala Phe Ser Ser Ile Asp Lys Gln Val Tyr Ala Thr Met Pro Ile
645 650 655
Asn Ser Phe Arg Ser Gly Met Asn Ser Pro Leu Arg Thr Thr Pro Asp
660 665 670
Lys Ser His Phe Gly Leu Ile Val Gly Asp Ser Gln His Ser Phe Pro
675 680 685
Phe Ser Gly Asp Glu Thr Asn His Ala Ser Ala Thr Ser Thr Gln Asp
690 695 700
Phe Leu Asp Gln Val Thr Ser Gln Lys Lys Ala Glu Ala Gln Pro Val
705 710 715 720
His Gln Ala Tyr Gln Met Ser Ser Phe Glu Gln Pro Phe Arg Ala Pro
725 730 735
Tyr His Gly Ser Arg Ala Gly Ile Ala Thr Gln Phe Ser Thr Ala Asn
740 745 750
Gly Gln Val Asn Leu Arg Gly Pro Gly Thr Ser Ala Glu Phe Ser Glu
755 760 765
Phe Pro Leu Val Asn Val Asn Asp Asn Arg Ala Gly Met Thr Ser Ser
770 775 780
Pro Asp Ala Thr Thr Gly Gln Thr Phe Gly
785 790
<210> 7
<211> 18
<212> DNA
<213> 人工序列(Artificial)
<220>
<223> 引物
<400> 7
ccagatcaaa gccacaac 18
<210> 8
<211> 20
<212> DNA
<213> 人工序列(Artificial)
<220>
<223> 引物
<400> 8
ctggacgata gagtaagacc 20
<210> 9
<211> 20
<212> DNA
<213> 人工序列(Artificial)
<220>
<223> 引物
<400> 9
acacctgctt ttttgactcg 20
<210> 10
<211> 20
<212> DNA
<213> 人工序列(Artificial)
<220>
<223> 引物
<400> 10
aaccagtgga aagagaatgc 20
<210> 11
<211> 20
<212> DNA
<213> 人工序列(Artificial)
<220>
<223> 引物
<400> 11
tcttggttga ccaaaaccac 20
<210> 12
<211> 20
<212> DNA
<213> 人工序列(Artificial)
<220>
<223> 引物
<400> 12
ggcccctcct gcaaattatc 20
<210> 13
<211> 20
<212> DNA
<213> 人工序列(Artificial)
<220>
<223> 引物
<400> 13
tttgggaggg tctggttatc 20
<210> 14
<211> 21
<212> DNA
<213> 人工序列(Artificial)
<220>
<223> 引物
<400> 14
ccacatatga agagagcaaa g 21
<210> 15
<211> 20
<212> DNA
<213> 人工序列(Artificial)
<220>
<223> 引物
<400> 15
caggctttgg acagaactag 20
<210> 16
<211> 20
<212> DNA
<213> 人工序列(Artificial)
<220>
<223> 引物
<400> 16
tacacagagt aaccccactc 20

Claims (10)

1.一种用于检测良性甲状腺结节的试剂盒,其特征在于,所述试剂盒包括选自下组的一对或多对引物:
(i)特异性扩增SPOP基因或转录本的引物,所述的引物扩增出长度为80-2000bp且含有SEQ ID NO.:1中第281位的扩增产物;
(ii)特异性扩增EZH1基因或转录本的引物,所述的引物扩增出长度为80-2000bp且含有SEQ ID NO.:3中第1712位的扩增产物;
(iii)特异性扩增ZNF148基因或转录本的引物,所述的引物扩增出长度为1000-3000bp且含有SEQ ID NO.:5中第1273-2871位的扩增产物。
2.如权利要求1所述的试剂盒,其特征在于,所述试剂盒还含有选自下组的试剂:
(a)与SEQ ID NO.:1中第281位的C→G突变结合的探针或芯片;
(b)识别SEQ ID NO.:1中第281位C→G突变的限制性内切酶;
(c)与SEQ ID NO.:3中第1712位的A→G突变结合的探针或芯片;
(d)识别SEQ ID NO.:3中第1712位A→G突变的限制性内切酶。
3.如权利要求1所述的试剂盒,其特征在于,所述试剂盒还含有选自下组的试剂:
(I)检测SEQ ID NO.:2中第94位P→R突变的特异性抗体;
(II)检测SEQ ID NO.:4中第571位Q→R突变的特异性抗体。
4.如权利要求1所述的试剂盒,其特征在于,所述试剂盒用于良性甲状腺结节的辅助判断。
5.如权利要求1所述的试剂盒,其特征在于,所述试剂盒还包括一说明书,说明书中记载以下内容:
当检测对象具有一种或多种所述突变,则提示检测对象的甲状腺结节为良性。
6.一种多核苷酸分子的用途,其特征在于,用于制备检测良性甲状腺结节的试剂盒;其中,所述的多核苷酸分子包括:
(i)SPOP基因、特异性扩增SPOP基因或转录本的引物、与SPOP基因的核苷酸序列即SEQID NO.:1中第281位C→G突变特异性结合的探针或芯片、和/或检测SEQ ID NO.:2中第94位P→R突变的特异性抗体;
(ii)EZH1基因、特异性扩增EZH1基因或转录本的引物、与EZH1基因的核苷酸序列即SEQID NO.:3中第1712位A→G突变特异性结合的探针或芯片、和/或检测SEQ ID NO.:4中第571位Q→R突变的特异性抗体;和/或
(iii)、特异性扩增ZNF148基因或转录本的引物、与ZNF148基因的核苷酸序列即SEQ IDNO.:5中第1273-2871位突变特异性结合的探针。
7.一种良性甲状腺结节相关基因的用途,其特征在于,用于制备检测良性甲状腺结节的试剂或试剂盒,并且所述的良性甲状腺结节相关基因包括SPOP基因、EZH1基因、和/或ZNF148基因。
8.如权利要求7所述的用途,其特征在于,所述的试剂或试剂盒用于检测以下单核苷酸突变:
SPOP基因的核苷酸序列:即SEQ ID NO.:1中第281位C→G。
9.如权利要求7所述的用途,其特征在于,所述的试剂或试剂盒用于检测以下单核苷酸突变:
EZH1基因的核苷酸序列:即SEQ ID NO.:3中第1712位A→G。
10.一种体外非诊断性检测样品是否存在良性甲状腺结节相关基因突变的方法,其特征在于,包括步骤:
(a)用特异性引物扩增样品的SPOP基因、EZH1基因、和/或ZNF148基因,得到扩增产物;和
(b)检测扩增产物中是否存在以下突变位点:
SPOP基因的核苷酸序列:即SEQ ID NO.:1中第281位C→G;
EZH1基因的核苷酸序列:即SEQ ID NO.:3中第1712位A→G;
ZNF148基因的核苷酸序列:即SEQ ID NO.:5中第1273-2871位突变。
CN201611115776.3A 2016-12-07 2016-12-07 良性甲状腺结节特异基因 Pending CN108165621A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201611115776.3A CN108165621A (zh) 2016-12-07 2016-12-07 良性甲状腺结节特异基因
PCT/CN2017/114889 WO2018103679A1 (zh) 2016-12-07 2017-12-07 良性甲状腺结节特异基因
US16/467,573 US20190352704A1 (en) 2016-12-07 2017-12-07 Benign thyroid nodule-specific gene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611115776.3A CN108165621A (zh) 2016-12-07 2016-12-07 良性甲状腺结节特异基因

Publications (1)

Publication Number Publication Date
CN108165621A true CN108165621A (zh) 2018-06-15

Family

ID=62490713

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611115776.3A Pending CN108165621A (zh) 2016-12-07 2016-12-07 良性甲状腺结节特异基因

Country Status (3)

Country Link
US (1) US20190352704A1 (zh)
CN (1) CN108165621A (zh)
WO (1) WO2018103679A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110878358A (zh) * 2019-12-19 2020-03-13 上海宝藤生物医药科技股份有限公司 一组甲状腺癌标志物及其应用
CN113981084A (zh) * 2021-11-03 2022-01-28 江苏省原子医学研究所 一种用于诊断甲状腺结节良恶性的分子标志物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1341716A (zh) * 2001-10-17 2002-03-27 湖南师范大学 一个锌指蛋白家族的人类新基因znf328
CN101821628A (zh) * 2007-08-30 2010-09-01 Ait奥地利技术研究所有限公司 肿瘤-标志物的组
CN104321439A (zh) * 2012-03-15 2015-01-28 凯杰科技有限公司 甲状腺癌生物标志物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1341716A (zh) * 2001-10-17 2002-03-27 湖南师范大学 一个锌指蛋白家族的人类新基因znf328
CN101821628A (zh) * 2007-08-30 2010-09-01 Ait奥地利技术研究所有限公司 肿瘤-标志物的组
CN104321439A (zh) * 2012-03-15 2015-01-28 凯杰科技有限公司 甲状腺癌生物标志物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEUNG-HYUN JUNG等: "Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma", 《ONCOTARGET》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110878358A (zh) * 2019-12-19 2020-03-13 上海宝藤生物医药科技股份有限公司 一组甲状腺癌标志物及其应用
CN113981084A (zh) * 2021-11-03 2022-01-28 江苏省原子医学研究所 一种用于诊断甲状腺结节良恶性的分子标志物及其应用

Also Published As

Publication number Publication date
US20190352704A1 (en) 2019-11-21
WO2018103679A1 (zh) 2018-06-14

Similar Documents

Publication Publication Date Title
KR102622309B1 (ko) 염색체 상호작용의 검출
Aune et al. Long non-coding RNAs in innate and adaptive immunity
US9957572B2 (en) Personalized tumor biomarkers
JP6867045B2 (ja) 血漿dnaの単分子配列決定
Spencer et al. A spatial and temporal map of C. elegans gene expression
AU2022203184A1 (en) Sequencing controls
KR102023584B1 (ko) 위장관췌장 신경내분비 신생물 (GEP-NENs)의 예측 방법
AU2012345789B2 (en) Methods of treating breast cancer with taxane therapy
KR20170120595A (ko) 암 상태를 결정하기 위한 방법 및 시스템
Thompson et al. A bZIP/bRLZ transcription factor required for DIF signaling in Dictyostelium
CN101772578A (zh) 作为标记物用在乳腺癌风险评估、诊断、预后和治疗中的在CHR 5p12和10q26上的遗传变异体
CN110079594B (zh) 基于dna和rna基因突变检测的高通量方法
CN107312861B (zh) 一种b-all患者预后风险评估标记物
KR102549013B1 (ko) 췌장암 진단을 위한 메틸화 마커 유전자 및 이의 용도
CN113889187B (zh) 单样本等位基因拷贝数变异检测方法、探针组和试剂盒
CN111662983A (zh) 一种用于检测淋巴瘤基因变异的试剂盒及其应用
Jiao et al. Discovering metabolic disease gene interactions by correlated effects on cellular morphology
CN108165621A (zh) 良性甲状腺结节特异基因
US20230054595A1 (en) Novel druggable targets for the treatment of inflammatory diseases such as systemic lupus erythematosus (sle) and methods for diagnosis and treatment using the same
CN109680072A (zh) 检测猪肌内脂肪含量的分子标志物及应用
Kassem et al. Novel mutations of the nucleophosmin (NPM-1) gene in Egyptian patients with acute myeloid leukemia: a pilot study
CN108841823A (zh) circRNA_26852及其应用
CN104212884B (zh) 胰腺神经内分泌肿瘤易感基因位点及检测方法和试剂盒
CN108624686B (zh) 一种检测brca1/2突变的探针库、检测方法和试剂盒
US20030175761A1 (en) Identification of genes whose expression patterns distinguish benign lymphoid tissue and mantle cell, follicular, and small lymphocytic lymphoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180615

RJ01 Rejection of invention patent application after publication